Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
- Shionogi Acquires Global Rights for OncoTheraphy’s Cancer Vaccines
April 2, 2012
- Kyowa Kirin’s Expected Mainstay POTELIGEO Approved
April 2, 2012
- GSK, DSP Begin Copromotion of Paxil CR Tablets from April
April 2, 2012
- Toray, Taiho Terminate Co-Development of β3-Adrenoceptor Agonist
April 2, 2012
- NanoCarrier Enters into Joint Research Agreement with Eisai for Its Drug Discovery Platform Technology
April 2, 2012
- Astellas Enters into Partnership with US Company to Develop, Market Fidaxomicin in Japan
April 2, 2012
- Novartis Files for Add’l Indication of DME for Lucentis
April 2, 2012
- Tempstaff, IUK to Form PV Management Joint Venture in May
March 30, 2012
- Astellas, Pfizer Extend Lipitor Licensing Term
March 30, 2012
- Daiichi Sankyo Enters Research Collaboration Agreement on Diabetes Therapy with US Venture Company
March 30, 2012
- Otsuka Chemical to Split Up Glycotechnology Laboratory to Make It New Company
March 30, 2012
- More Than 70% of Doctors Say “Frequency of Meetings Will Not Change” Despite Review of Entertainment: CareNet Survey
March 29, 2012
- Takeda’s Novel Renal Anemia Drug Omontys Approved in the US
March 29, 2012
- Astellas Files MAA for Fixed-Dose Combination of Vesicare/Harnal in Europe
March 29, 2012
- Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
- No Change in Wholesalers’ Business Entertaining Rules for Time Being; Status of MSs with MR Qualification Remains Unclear
March 29, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…